@kervio, thanks for your comments on this. I am also really shocked at the primary endpoint being set at a 43% improvement in mortality. I can't see how they would ever realistically have got overwhelming efficacy (e.g. using a sceptical prior) at any interim analysis if this was the goal.
I'm no expert at Bayesian analysis but I had a go at estimating some probability distributions for achieving various levels of mortality reduction for various observed deaths in the treatment arm at the 45% analysis stage (which obviously passed futility). I inferred some mean and standard deviations for both sceptical and enthusiastic priors under various scenarios. I have plotted these below for a particular scenario where 17 deaths were observed in the treatment arm and where there were theoretical deaths of 40.5 (i.e. mortality at 60%) in the control arm. This, I think, would be the 'worst case scenario' / maximum no of deaths that could have been observed at that the 45% stage for continuation of the trial. This also assumes NIH/MSB based futility analysis on an enthusiastic prior and selected 5% as the minimum required probability of achieving the endpoint.
If 17 deaths vs. 40.5 is in fact the worst case, that's still quite a treatment benefit!
- Forums
- ASX - By Stock
- MSB
- Overwhelming efficacy - the stats required
Overwhelming efficacy - the stats required, page-577
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.11 |
Change
0.055(5.24%) |
Mkt cap ! $1.261B |
Open | High | Low | Value | Volume |
$1.05 | $1.13 | $1.04 | $6.781M | 6.207M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 43856 | $1.11 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.11 | 66000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 52505 | 1.100 |
1 | 4552 | 1.095 |
3 | 60574 | 1.090 |
3 | 31716 | 1.085 |
2 | 14000 | 1.080 |
Price($) | Vol. | No. |
---|---|---|
1.110 | 66000 | 1 |
1.115 | 80808 | 1 |
1.120 | 88882 | 4 |
1.125 | 74996 | 5 |
1.130 | 111884 | 6 |
Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |